DualStim Therapy with Wharton's Jelly for Erectile Dysfunction

Phase 2, randomised, single-blind trial of GeneXSTEM in erectile dysfunction (ED) (2 arms), sponsored by BioIntegrate. Primary endpoints: Adverse or Severe adverse events associated with Intracavernosal administration at 18 months and Change in International Index of Erectile Function Questionnaire score at 18 months. Status: unknown.